ReSPECT Glioblastoma Clinical Trial Data to be Presented at 2020 Society for Neuro-Oncology Annual Meeting (GlobeNewswire) - Oct 1, 2020 - "Plus Therapeutics, Inc...announced that its abstract regarding lead investigational drug, Rhenium NanoLiposomes (RNL™), was accepted to the 2020 Society for Neuro-Oncology (SNO) Annual Meeting being held virtually on November 19-21, 2020....The Company will be providing a detailed interim safety, tolerability, dosing and efficacy data from its ReSPECT Phase 1 clinical trial of a novel radiotherapy, RNL, in adults with recurrent glioblastoma (GBM) after standard surgical, radiation, and chemotherapy treatment...The Company plans to complete enrollment in the Phase 1 trial by the end of 2020..."
Enrollment status • P1 data • Glioblastoma • Oncology
|